Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Melioidosis is endemic in at least 45 countries, but greatly under-reported. Up to 50% of cases seen in hospital die. Our Researchers at MORU have produced a rapid diagnostic test that aims to improve both diagnosis and public awareness. Better coordination between researchers and policy makers is needed to face upcoming emerging infectious diseases.

Direk Limmathurotsakul: Our Microbiology Department does research in the wide area of microbiology diseases including melioidosis, leptospirosis and scrub typhus. We do the research from the bench to the bed, up to the patients, population and policy makers. My personal area is melioidosis research. Melioidosis is a bacterial infectious disease. The bacteria is in the soil and water. People who are farmers in South East Asia are exposed to the soil all the time and they can get bacteria into their bodies, present with severe sepsis or pneumonia and they die.

Because the disease is very difficult to diagnose, patients normally come with severe sepsis or pneumonia which can be caused by many infectious diseases. You need good microbiology facilities to do the bacterial culture - to grow the bacteria. You cannot diagnose with clinical presentation, so the doctor cannot tell you upfront that you got melioidosis. You have to wait 2-7 days before the bacteria grow from your blood or from sputum or from urine. Most of the patients who die, they die quickly, within 1-2 days. When they die, patients are taken back home or to the temple, and when the culture results come back the doctors know but the patient doesn't know. So that makes people's awareness of this diseases very, very low. We see also in many developing countries we don't have microbiology facilities tied to hospitals. If you go to Africa, when you have a fever you might give one drop of blood to see if you have malaria or not; then if you don't have malaria, you get some antibiotics.

My work mainly tries to improve diagnosis and treatment. Then when you know what the disease burden is in your area, we improve public awareness, we try to connect with policy makers, and then we implement education programmes so that people can protect themselves more by wearing boots, drinking boiled water, so that we can see whether we can reduce incidence of melioidosis and save more lives.

Q: Are you or your group working on a rapid diagnostic test?

DL: Now we have a kit called a key reader that's like a mobile phone attached to a diagnostic kit. Once it's positive it will send an sms, so researchers can check how many cases you have in that area.

However, it's important not only to have this test available but also that people know that this disease is endemic in their country - and then recommend the test. For example, we saw patients in our hospital, in just one hospital: out of 400 cases per year, 200 died. But the national database report shows that only 6 cases die of melioidosis per year. That is because of the bad reporting system: doctors know that patients died but they don't write on the report. We recommended that 45 melioidosis endemic countries should not just enhance their diagnostic capacities but also enhance their national reporting systems as well.

Q: What important lines of research have emerged in the last few years?

DL: We can say for sure that we will have new emerging infectious diseases every 1-2 years. You can see, you can count: Ebola, Zika virus, maybe a new SARS, maybe a new flu soon. We should have our research ready to attack those new emerging infectious diseases, and also collaborate between the multiple researchers and organisation worldwide.

Q: Why does your line of work matter and why should we fund it?

DL: I think because microbiology is a part of infectious diseases: many infectious diseases are from bacteria, virus or parasite – not only just malaria. Also we know that it kills a lot of people worldwide and that it is preventable. These infectious diseases hit the lower and middle-income countries and a lot of poor people worldwide are dying from these diseases which we should be able to prevent. That's why we should improve our research and guide policy makers to save lives.

Q: How does your work fit into translational medicine within the department?

DL: In translational medicine, we mean that we use up-to-date advanced knowledge into the implementation so that it can save lives. So we try to bridge all of the bench work, the basic science about cells, about organelles in the cells. We try to make sure that this knowledge is not just in publications, but we take it down, we try to see whether we can improve diagnosis, we can improve treatment. And at the same time when we see a lot of patients we try to improve surveillance and give the information right to policy makers, so that at the end patients have a better life and we can improve outcome of their lives.

Q: What are the benefits of working at MORU for you as microbiologist?

DL: Would you like the beautiful answer or the real?

Q: The real.

DL: During the last 15 years that I have worked with MORU, it feels like a springboard for up-to-date advanced science into the global community. I have access to policy makers worldwide. I work with well-known professors from Oxford University and other universities from both the US and UK. That's why I think that working with an international organisation like MORU is the best experience of my life.

Direk Limmathurotsakul


Dr Direk Limmathurotsakul's research focuses on the epidemiology of melioidosis, a bacterial infection caused by Burkholderia pseudomallei. Microbiological culture is required to confirm the diagnosis, and disease incidence is thus generally grossly underestimated. Dr Limmathurotsakul leads public engagement campaigns to make Thai people more aware of the disease and how to prevent it.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.